SOURCE: Spencer Pharmaceutical Inc.

October 14, 2010 09:30 ET

Spencer Pharmaceutical Announces Development of Ibuprofen Once a Day Tablet Formulation

BOSTON, MA--(Marketwire - October 14, 2010) - Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) is now developing an Ibuprofen once a day monolithic tablet formulation.

According to the company, clinical trial and epidemiological data of several cycloxygenase (COX) inhibitors in long-term treatment showed an increased cardiovascular (CV) risks such as thrombotic events, myocardial infarction, and stroke, which can be fatal. All nonsteroidal anti-inflammatory drugs (NSAIDS), both COX-2 selective and nonselective, may have a similar risk. The recommendation is to minimize potential risk for adverse CV events, using the lowest effective dose should be used over duration of treatment with NSAID.

"Spencer Pharmaceutical is now developing an Ibuprofen once a day monolithic tablet formulation permitting the reduction of several adverse effects preventing gastrointestinal complications (bleeding, ulceration or perforation) and or CV risks," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition "The pharmaceutical form will first release the lowest effective dose followed by sustained liberation of the drug at the required therapeutic level, up to 24 hours," further stated Dr. Arella.

About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.

Contact Information

  • Contact:
    Dr. Max Arella
    Spencer Pharmaceutical Inc.
    Tel. 1+(617) 973-5017